9.3 Hemostatic and Thrombotic Disorders: Hemophilias, von Willebrand Disease, DIC, and Thrombophilias

Hemostatic and Thrombotic Disorders: Hemophilias, von Willebrand Disease, DIC, and Thrombophilias

Hemostatic disorders fall into two major clinical categories: hemorrhagic diatheses (bleeding disorders caused by quantitative or qualitative platelet defects, coagulation factor deficiencies, or accelerated fibrinolysis) and hypercoagulable states (thrombophilias predisposing to inappropriate microvascular, venous, or arterial thrombosis). Accurate diagnosis requires correlating clinical bleeding manifestations with quantitative automated coagulometry, platelet aggregometry, mixing algorithms, and molecular testing.

---

1. Quantitative and Qualitative Platelet Disorders

Thrombocytopenia: Etiological Mechanisms

Thrombocytopenia is defined as a peripheral blood platelet count of $<150 \times 10^9/\text{L}$. Significant clinical purpura, petechiae, and mucosal oozing typically manifest when counts drop below $50 \times 10^9/\text{L}$, with high risk for spontaneous intracranial or internal hemorrhage at counts $<10\text{ to }20 \times 10^9/\text{L}$.

1. Impaired Bone Marrow Production: Characterized by decreased megakaryocytes on bone marrow examination. Etiologies include aplastic anemia, acute leukemias, marrow infiltration (myelophthisis), cytotoxic chemotherapy, and megaloblastic anemia (ineffective thrombopoiesis accompanied by hypersegmented neutrophils).
2. Immune Thrombocytopenic Purpura (ITP): Acquired autoimmune disorder driven by pathogenic IgG autoantibodies directed against platelet membrane glycoproteins, primarily GP IIb/IIIa or GP Ib/IX. Opsonized platelets are sequestered and phagocytosed by splenic reticuloendothelial macrophages via Fc$\gamma$ receptors. Bone marrow examination reveals normal to increased megakaryocytes (compensatory megakaryocytic hyperplasia). Peripheral smear shows marked thrombocytopenia with occasional stress megathrombocytes. PT, aPTT, and fibrinogen are completely normal.
3. Thrombotic Microangiopathies (TMA):
   • Thrombotic Thrombocytopenic Purpura (TTP): Caused by severe deficiency ($<10\%$ enzymatic activity) of ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13). ADAMTS13 is responsible for cleaving ultra-large von Willebrand factor (UL-vWF) multimers secreted by endothelial Weibel-Palade bodies into smaller, less adhesive plasma multimers. Severe deficiency (most often acquired via inhibitory IgG autoantibodies) allows uncleaved UL-vWF multimers to anchor to the endothelium, spontaneously tethering passing platelets into widespread, occlusive microvascular platelet thrombi throughout the microcirculation. Clinical presentation features the classic Pentad:
     1. Microangiopathic Hemolytic Anemia (MAHA) with marked schistocytes ($>1\%$ on peripheral smear), polychromasia, and nucleated red blood cells
     2. Severe Thrombocytopenia (frequently $<20 \times 10^9/\text{L}$)
     3. Fluctuating Neurological Signs (headache, confusion, transient ischemic attacks, seizures, coma)
     4. Renal Impairment (hematuria, proteinuria, mild azotemia)
     5. Fever
     • Crucial Coagulation Profile: In TTP, thrombi are composed purely of platelets and vWF without systemic activation of the coagulation cascade. Therefore, PT, aPTT, and Fibrinogen are completely NORMAL! This is the definitive discriminator separating TTP from DIC. Emergency therapy is Therapeutic Plasma Exchange (TPE) with Fresh Frozen Plasma (FFP), which removes autoantibodies and supplies active ADAMTS13; platelet transfusions are strictly contraindicated as they precipitate new microvascular thrombosis.
   • Hemolytic Uremic Syndrome (HUS): Typical HUS occurs predominantly in pediatric patients following gastroenteritis caused by Shiga toxin-producing Escherichia coli (STEC, serotype O157:H7) or Shigella dysenteriae. Shiga toxin binds to globotriaosylceramide (Gb3) receptors on renal glomerular capillary endothelium, triggering endothelial cytotoxicity, localized platelet-fibrin microthrombi, and acute cortical necrosis. Presents with the pediatric Triad: MAHA with schistocytes, thrombocytopenia, and severe Acute Renal Failure / oliguria. ADAMTS13 activity is normal ($>10\%$); PT, aPTT, and fibrinogen are normal.
   • Heparin-Induced Thrombocytopenia (HIT Type II): An immune-mediated adverse drug reaction developing 5 to 10 days following exposure to unfractionated heparin (or within 24 hours upon heparin re-exposure). Pathogenic IgG antibodies form against macromolecular complexes of Platelet Factor 4 (PF4) and Heparin. The Fc regions of these IgG antibodies engage Fc$\gamma$RIIa receptors on platelets, triggering intense platelet activation, prothrombotic microparticle release, and secondary thrombin generation. Paradoxically, this causes a catastrophic prothrombotic state (venous thromboembolism, limb gangrene, stroke; "white clot syndrome") accompanied by a relative platelet count drop $>50\%$ from baseline. Laboratory diagnosis employs the 4Ts clinical scoring system, PF4/heparin enzyme immunoassays, and the confirmatory gold-standard functional $^{14}\text{C}$-Serotonin Release Assay (SRA). Management requires immediate cessation of all heparin and initiation of alternative non-heparin anticoagulation with direct thrombin inhibitors (argatroban, bivalirudin) or fondaparinux.

Qualitative Platelet Disorders: Bernard-Soulier vs. Glanzmann

                     ┌──────────────────────────────────────────────┐
                     │     Qualitative Platelet Defect Workup       │
                     └──────────────────────┬───────────────────────┘
                                            │
            ┌───────────────────────────────┴───────────────────────────────┐
            ▼                                                               ▼
┌──────────────────────────────┐                                ┌──────────────────────────────┐
│   Bernard-Soulier Syndrome   │                                │   Glanzmann Thrombasthenia   │
└──────────────┬───────────────┘                                └──────────────┬───────────────┘
               │                                                               │
 • Defect: GP Ib/IX/V complex                                   • Defect: GP IIb/IIIa complex
 • Impairment: Platelet Adhesion to vWF                         • Impairment: Platelet Aggregation (fibrinogen)
 • Blood Smear: Giant Platelets (4-8 µm)                        • Blood Smear: Normal morphology, isolated platelets
 • Platelet Count: Mildly DECREASED                             • Platelet Count: NORMAL
 • Aggregometry:                                                • Aggregometry:
   - ADP, Collagen, Epinephrine: NORMAL                           - ADP, Collagen, Epinephrine: ABSENT / FLAT
   - Ristocetin: ABSENT (No correction with normal plasma)        - Ristocetin: NORMAL agglutination
 • Flow Cytometry: Absent CD42b (GP Ib), CD42a (GP IX)          • Flow Cytometry: Absent CD41 (GP IIb), CD61 (GP IIIa)

• Bernard-Soulier Syndrome (BSS):
  • Inheritance and Defect: Autosomal recessive deficiency or molecular dysfunction of the Glycoprotein GP Ib/IX/V receptor complex.
  • Pathophysiology: Platelets cannot bind subendothelial von Willebrand factor under high shear rates, completely blocking initial primary hemostatic adhesion.
  • Diagnostic Smear & Morphology: Peripheral blood smear demonstrates hallmark Giant Platelets (diameter 4 to 8 $\mu$m, frequently approaching the size of erythrocytes) and mild-to-moderate thrombocytopenia ($20\text{ to }100 \times 10^9/\text{L}$).
  • Platelet Aggregometry: Completely absent agglutination with Ristocetin, which FAILS TO CORRECT upon addition of normal pooled plasma (because the platelet membrane itself lacks the functional receptor). Aggregation in response to physiological agonists (ADP, Collagen, Epinephrine, Arachidonic acid) is completely NORMAL.
• Glanzmann Thrombasthenia (GT):
  • Inheritance and Defect: Autosomal recessive deficiency or structural mutation of the Glycoprotein GP IIb/IIIa integrin complex ($\alpha_{\text{IIb}}\beta_3$).
  • Pathophysiology: Platelets adhere normally to subendothelial collagen and vWF, but activated platelets cannot bind plasma fibrinogen to form inter-platelet cross-links, completely abolishing platelet aggregation.
  • Diagnostic Smear & Morphology: Peripheral blood smear shows a completely normal platelet count and normal morphology; however, platelets on stained smears remain scattered individually as single elements without forming the normal aggregated clusters.
  • Platelet Aggregometry: Severely flat, completely absent aggregation with all physiological agonists (ADP, Collagen, Epinephrine, Thrombin). Agglutination in response to Ristocetin is entirely NORMAL (since GP Ib and vWF are intact).

---

2. Congenital Coagulation Factor Deficiencies

Hemophilia A, B, and C

• Clinical Severity Classification for Hemophilia A and B:
  • Severe ($<1\%$ factor activity, $<0.01\text{ IU/mL}$): Frequent spontaneous, unprovoked bleeding into large hinge joints (hemarthroses in knees, elbows, ankles), leading to chronic, debilitating hemophilic arthropathy; deep intramuscular hematomas; retroperitoneal hemorrhages; and life-threatening intracranial bleeding.
  • Moderate (1% to 5% factor activity): Rare spontaneous bleeds; severe hemorrhage following mild blunt trauma or minor surgical procedures.
  • Mild (5% to 40% factor activity): Asymptomatic in daily life; prolonged, severe hemorrhage discovered only after major surgical interventions, tooth extractions, or severe trauma.
• Emicizumab Mechanism: A recombinant, humanized bispecific monoclonal antibody that binds simultaneously to Factor IXa and Factor X, mimicking the cofactor function of activated Factor VIIIa. Because its molecular structure differs from Factor VIII, it is effective in Hemophilia A patients who have developed inhibitory alloantibodies against Factor VIII.

von Willebrand Disease (vWD)

von Willebrand Disease is the most prevalent inherited human bleeding disorder, affecting approximately 1% of the population. Inherited in autosomal dominant or recessive patterns, it results from quantitative reductions or qualitative structural defects in von Willebrand factor (vWF).

• Dual Physiological Roles of vWF:
  1. Platelet Adhesion: vWF acts as a molecular bridge tethering platelet membrane GP Ib/IX/V to subendothelial collagen under high vascular shear rates.
  2. Factor VIII Carrier: vWF forms a non-covalent circulating complex with Factor VIII, stabilizing its quaternary structure and extending its intravascular plasma half-life from ~2 hours to 10–12 hours. Without vWF, Factor VIII is rapidly cleared from the circulation.
• Clinical Manifestations: In contrast to hemophilia (which manifests with deep joint and muscle bleeds), vWD characteristically presents with mucocutaneous bleeding: recurrent epistaxis, menorrhagia, gingival bleeding, easy cutaneous ecchymoses, and prolonged bleeding from small lacerations.
• Classification of vWD:
  • Type 1 (~75% to 80% of cases): Autosomal dominant partial quantitative deficiency of structurally normal vWF multimers. Responsive to Desmopressin (DDAVP), which induces exocytosis of endogenous vWF and Factor VIII stored in endothelial Weibel-Palade bodies.
  • Type 2 (~15% to 20%): Qualitative defects in vWF structure or function:
    • Type 2A: Decreased platelet-dependent function accompanied by loss of high-molecular-weight (HMW) multimers due to abnormal multimer assembly or increased cleavage by ADAMTS13.
    • Type 2B: Gain-of-function mutation in the vWF A1 domain causing hyper-affinity for platelet GP Ib; vWF binds spontaneously to circulating platelets, leading to rapid clearance of both HMW multimers and platelets, causing mild, episodic thrombocytopenia and enhanced Ristocetin-Induced Platelet Agglutination (RIPA) at low ristocetin concentrations ($0.5\text{ mg/mL}$).
    • Type 2M: Decreased platelet-dependent function with normal multimer distribution.
    • Type 2N (Normandy): Autosomal mutation impairing vWF binding to Factor VIII; circulating Factor VIII is rapidly cleared, mimicking mild hemophilia A but exhibiting autosomal rather than X-linked inheritance.
  • Type 3 (<1%): Severe autosomal recessive total quantitative absence of vWF. vWF antigen is undetectable, and secondary Factor VIII activity is profoundly depressed ($<5\%$), producing severe mucosal hemorrhage and hemarthroses.
• Diagnostic Laboratory Profile for vWD:
  • Platelet Count: Normal (except mild thrombocytopenia in Type 2B).
  • PT: Completely normal.
  • aPTT: Normal or mildly prolonged (depending on the degree of secondary Factor VIII reduction).
  • Bleeding Time / PFA-100: Markedly prolonged closure times with Collagen/Epinephrine and Collagen/ADP cartridges.
  • vWF Antigen (vWF:Ag): Quantitative immunoassay (ELISA or latex turbidimetry) measuring total vWF protein concentration (decreased in Types 1 and 3; normal in Type 2).
  • vWF Ristocetin Cofactor Activity (vWF:RCo): Functional assay measuring agglutination of formalin-fixed donor platelets in the presence of ristocetin and patient plasma (ratio of $\text{vWF:RCo} / \text{vWF:Ag} < 0.7$ indicates a qualitative Type 2 defect).
  • RIPA Aggregometry: Defective at standard ristocetin concentrations; CRITICAL DISTINCTION: Defective RIPA in vWD CORRECTS completely upon adding normal pooled plasma or cryoprecipitate (which supplies exogenous vWF), whereas Bernard-Soulier syndrome fails to correct!

---

3. Acquired Bleeding Disorders: Liver Disease, Vitamin K Deficiency, and DIC

Severe Hepatic Disease vs. Isolated Vitamin K Deficiency

Because the liver parenchyma synthesizes nearly all procoagulant factors and natural anticoagulant inhibitors, distinguishing primary hepatocellular failure from isolated nutritional or biliary Vitamin K deficiency is a frequent clinical challenge:

                             Prolonged PT/INR and aPTT
                                        │
                            Measure Factor V Activity
                                        │
                     ┌──────────────────┴──────────────────┐
                     ▼                                     ▼
          **Factor V is NORMAL**                **Factor V is DECREASED**
                     │                                     │
                     ▼                                     ▼
       **Pure Vitamin K Deficiency**             **Severe Liver Disease**
       • Obstructive Jaundice / Cholestasis      • Cirrhosis / Acute Hepatic Necrosis
       • Malabsorption / Antibiotic therapy      • Impaired synthesis of all factors
       • Rapid correction with IV Vitamin K      • Unresponsive to parenteral Vitamin K

• Vitamin K Deficiency: Factors II, VII, IX, and X, along with Proteins C and S, are undercarboxylated. Because Factor VII has the shortest half-life (~6 hours), PT prolongs first, followed by aPTT. Factor V is synthesized in hepatocytes independent of Vitamin K; therefore, in pure Vitamin K deficiency, Factor V activity is completely NORMAL.
• Severe Liver Disease (Cirrhosis / Fulminant Hepatic Failure): Global suppression of hepatocyte protein synthesis depresses Factors I, II, V, VII, IX, X, XI, Antithrombin, and Protein C. Factor V activity is markedly DECREASED. (Factor VIII is synthesized predominantly in sinusoidal endothelial cells and remains normal or elevated as an acute-phase reactant).

Disseminated Intravascular Coagulation (DIC)

DIC is an acquired, life-threatening clinicopathological syndrome characterized by systemic, unregulated activation of coagulation, leading to diffuse microvascular fibrin deposition, multi-organ failure, and a severe consumption coagulopathy with secondary hyperfibrinolysis:

• Triggering Etiologies: Sepsis/severe infection (endotoxin/cytokine release), obstetric catastrophes (amniotic fluid embolism, abruptio placentae releasing placental tissue factor), Acute Promyelocytic Leukemia (APL / AML-M3: neoplastic promyelocytes contain tissue factor-rich granules that trigger massive clotting; treated emergently with all-trans retinoic acid [ATRA]), massive crush trauma, and envenomation.
• Pathophysiological Vicious Cycle:
  1. Massive intravascular exposure of Tissue Factor drives systemic, uncontrolled thrombin generation.
  2. Microvascular thrombi occlude organ capillary beds, causing multi-organ dysfunction (renal failure, respiratory distress, hepatic failure).
  3. Extensive clotting exhausts and consumes circulating platelets, fibrinogen, Factor V, Factor VIII, and Prothrombin.
  4. Widespread microvascular thrombi stimulate endothelial tPA release, driving massive secondary fibrinolysis. Plasmin cleaves fibrin into massive quantities of FDPs and D-dimers, which coat platelets and inhibit fibrin polymerization, precipitating catastrophic systemic bleeding (oozing from surgical wounds, puncture sites, hematuria, gastrointestinal hemorrhage).
• Acute Overt DIC Diagnostic Profile:
  • Platelet Count: Severe, rapidly progressive thrombocytopenia ($<50 \times 10^9/\text{L}$).
  • PT and aPTT: Markedly prolonged due to consumptive factor depletion.
  • Fibrinogen: Profound hypofibrinogenemia ($<100\text{ mg/dL}$).
  • D-Dimer and FDPs: Markedly elevated (diagnostic hallmark of concurrent thrombin and plasmin activity).
  • Peripheral Blood Smear: Microangiopathic Hemolytic Anemia (MAHA) with abundant Schistocytes (helmet cells, triangular RBC fragments) formed by physical shearing of red cells across intravascular fibrin webs.

---

4. Hereditary and Acquired Thrombophilias (Hypercoagulable States)

Thrombophilia refers to an inherited or acquired predisposition to inappropriate venous thromboembolism (VTE) or arterial thrombosis.

Factor V Leiden (Activated Protein C Resistance - APCR)

• Molecular Genetics: A single point mutation in the F5 gene: guanine to adenine substitution at nucleotide 1691 ($1691G>A$), causing an arginine-to-glutamine amino acid substitution at position 506 ($Arg506Gln$).
• Biochemical Mechanism: Residue 506 is the primary cleavage site targeted by Activated Protein C (APC) to inactivate Factor Va. The mutated Factor Va protein is resistant to APC-mediated proteolytic inactivation, remaining active in the prothrombinase complex and driving sustained, unregulated thrombin generation.
• Epidemiology and Risk: The most common inherited thrombophilia in Caucasian populations (~3% to 8% carrier frequency). Heterozygotes have a 3- to 8-fold increased risk of VTE; homozygotes have up to an 80-fold increased risk.
• Laboratory Diagnosis: Clot-based APCR screening test: aPTT is measured in the presence and absence of exogenous APC; an APCR ratio ($aPTT_{+APC} / aPTT_{-APC}$) $<2.0$ indicates resistance. Confirmed definitively via PCR DNA molecular testing.

Prothrombin G20210A Mutation

A single point mutation in the 3'-untranslated region of the prothrombin (F2) gene ($20210G>A$) that increases mRNA stability and processing, leading to a 30% elevation in circulating plasma prothrombin (Factor II) levels and a 2- to 3-fold increased lifetime risk of VTE.

Hereditary Deficiencies of Antithrombin, Protein C, and Protein S

Autosomal dominant loss-of-function mutations in SERPINC1 (Antithrombin), PROC (Protein C), or PROS1 (Protein S). Patients present with unprovoked, recurrent venous thromboembolism at a young age (<40 years).

• Warfarin-Induced Skin Necrosis: When Warfarin is initiated in a patient with an underlying Protein C or Protein S deficiency without concurrent heparin bridging, the short biological half-life of Protein C (~6 hours) causes its plasma concentration to drop precipitously before procoagulant factors II and X (half-lives 40–72 hours) decline. This induces a temporary, severe hypercoagulable state with widespread microvascular thrombosis of capillary beds supplying skin and subcutaneous adipose tissue, causing catastrophic ischemic cutaneous infarction (breasts, buttocks, thighs).

Antiphospholipid Syndrome (APS) and Lupus Anticoagulant (LA)

Antiphospholipid Syndrome is an acquired autoimmune thrombophilia characterized by persistent circulating autoantibodies directed against phospholipid-binding plasma proteins, primarily $\beta_2$-glycoprotein I ($\beta_2\text{GPI}$) and Prothrombin.

• Clinical Features: Recurrent venous thrombosis (DVT, PE), arterial thrombosis (ischemic stroke, transient ischemic attacks), and obstetric complications (unexplained recurrent first-trimester miscarriages, fetal death after 10 weeks gestation, severe preeclampsia).
• The In Vitro / In Vivo Diagnostic Paradox:
  • In Vitro: Lupus anticoagulants bind to reagent phospholipids used in clotting assays, sterically interfering with tenase and prothrombinase assembly and paradoxically PROLONGING phospholipid-dependent clotting tests (aPTT, dilute Russell Viper Venom Time dRVVT).
  • In Vivo: These autoantibodies activate platelets, endothelial cells, and monocytes, potently driving THROMBOSIS in vivo!
• ISTH Standardized 3-Step Laboratory Diagnostic Algorithm:
  1. Screening Step: Demonstration of a prolonged phospholipid-dependent clotting test (dRVVT screen or LA-sensitive aPTT with low phospholipid content). dRVVT directly activates Factor X via Daboia russelii venom, bypassing upstream factors.
  2. Mixing Step: Failure of the prolonged screening test to correct when mixed 1:1 with Pooled Normal Plasma (confirms the presence of a circulating inhibitor rather than a factor deficiency).
  3. Confirmatory Step: Significant shortening or normalization of the clotting time upon adding an excess of confirmatory bilayer phospholipids (e.g., dRVVT Confirm reagent or frozen-thawed platelet membranes in the Platelet Neutralization Procedure). The excess phospholipids absorb the lupus anticoagulant autoantibodies, neutralizing the inhibition and proving phospholipid dependence.

---

5. Diagnostic Differential Table: Bleeding and Thrombotic Disorders